WSLCB Seeking Panelists, Participants & Listeners For Deliberative Dialogue Sessions

Topics Cover Cannabis Quality Assurance Testing

Three sessions will use deliberative dialogue to discuss issues related to new state quality assurance testing of cannabis.

What is deliberative dialogue?

In short, deliberative dialogue is a method of structured conversation that seeks to find increased understanding of all sides and perspectives of an issue. It seeks to discover the most important values that participants have about the topics being discussed and to build relationships among participants. Listening with empathy and ensuring equity among participants is foundational. Deliberative dialogue brings up and discusses the consequences, costs and trade-offs of various policy options, and working through the emotions and values as a necessary part of making recommendations and decisions, common ground can be established as decisions are made.

Deliberative dialogue can be helpful when used between Government and stakeholders and community members. WSLCB is charged with ensuring the safety of Washington state residents. WSLCB works with the public and licensees on key decisions that affect the safety of Washingtonians, and the agency has a central role in creating regulatory frameworks to support that work. WSLCB believes that Washingtonians have the capacity to be well informed just as experts have the capacity to better appreciate the concerns of the public. Both expert knowledge and the perspectives of the public are crucial to the formulation of wise policy. For more on deliberative dialogue click here.

How are the sessions formatted?

Each session is scheduled for three hours.

  • A panel will be scheduled for each session, comprised of:
    • Panel 1: Consumers (4 – 5 panelists; consumers, health care reps, and others)
    • Panel 2: Processors (5- 6 panelists; processors/producers from all tiers, indoor/outdoor growers, minority-owned business, and differing regions in state)
    • Panel 3: Labs (4 – 5 panelists, consisting of lab owners, employees, or both).
  • The moderator will open each forum with topic background, panel introduction, and ground rules.
  • Panelists may give a five minute opening statement covering their background, their interest and experience on the topic, and ideas or thoughts they’d like to talk about.
  • Questions sent in from the panelist recruitment will be posed to the panel members.
  • The rest of the meeting will be interactive (using the hand-raising feature in WebEx) to allow participants and listeners to pose questions to the panel.

How are Panelists Selected?

WSLCB began panel recruitment on January 6, 2021. We asked for those interested in being a panelist, participant or listener to contact us by close of business, or 5PM on January 20, 2021. We continue to need panelists. You can view the announcement and apply here.

How can I listen or participate in Deliberative Dialogue at WSLCB?
Sign up as a non-panelist participant or listener for:

Questions? Contact rules@lcb.wa.gov.

WSLCB Actions: New Permanent Rule For Certificates Of Compliance For Cannabis Business Locations And Extension Of Emergency Rules On Prohibition Of Vitamin E Acetate

January 6, 2021 Board Action

On Jan. 6, during a regularly scheduled meeting, the Washington State Liquor and Cannabis Board took the following actions:

Adopted Emergency Rules (CR-103E) Regarding Vitamin E Acetate

Emergency Rules (WAC 314-55-1055) – Marijuana Product Disclosure Form (Effective January 6, 2021)

Emergency Rules (WAC 314-55-1065) – LCB Vitamin E Acetate Prohibition (formerly LCB Vitamin E Acetate Ban) (Effective January 6, 2021)

Emergency Rules (WAC 314-55-077) – Marijuana Processor License – Privileges, Requirements and Fees (Effective January 6, 2021)

Emergency Rules (WAC 314-55-079) – Marijuana Retailer License – Privileges, Requirements and Fees (Effective January 6, 2021)

 

Adopted Permanent Rule (CR-103P)  Certificate of Compliance – location of business upon application submission)

Implementation of SSB 6206 – Marijuana Business Premise Certificate of Compliance (Effective February 6, 2021)

WSLCB Looking For Panelists For Its First Deliberative Dialogue Sessions

Be a Panelist, Participant, or Listener

WASHINGTON:  Do you want to share your perspectives about cannabis quality assurance testing? Would you like to share your experiences with fellow licensees, consumers, and others? Would you like to be part of a different way of sharing information and gaining understanding?

If you answered “yes,” let us know!

WSLCB has been working on developing new cannabis product-testing rules. A public hearing on proposed rules was held on November 18, 2020. While we heard oral comment from many licensees, we would like to hear from everyone in the supply chain so we have a better understanding of the complete system – processors, producers, retailers, consumers, and others. And we want everyone in the supply chain to have an opportunity to hear the wide range of perspectives

We’d like to hear from everyone in the supply chain so we have a better understanding of the complete system – processors, producers, retailers, consumers, and others. And we want everyone in the supply chain to have an opportunity to hear the wide range of perspectives.

About the sessions

LCB’s Policy and Rules manager Kathy Hoffman will moderate three sessions with different panelists and topics. To get the conversation started the sessions begin with prepared questions for each panel, with time near the end for audience questions and participation (online of course). Our goal is to increase communication between consumers, licensees, labs, and the agency.

The three session dates and topics as follows:

  • January 28, 2020: Consumer Panel (4 -5 panelists)
  • February 4, 2020: Processor/Producer Panel (5-6 panelists)
  • February 11, 2020: Cannabis Testing Lab Panel (4 -5 panelists)

We want to make sure that each panel represents the rich diversity of our communities, license types, and growing practices. Can you help?

Please send the following information to rules@lcb.wa.gov, attention Kathy Hoffman by close of business (5PM) on TUESDAY, JANUARY 20, 2020:

  1. Your name
  2. Which of the three panels and dates you’d like to be considered for
  3. Your contact information (email and phone number)
  4. Tell us if you are a consumer, producer, processor, producer/processor, retailer or lab employee or owner
  5. If you are a processor, producer or processor/producer, tell us:
    • Your tier size (1, 2,or 3); whether you are an indoor or outdoor grower; and where you are located.
  6. Tell us three or four questions you’d like to ask others on your panel (for example, how do other producers sample? Or, when you purchase product, what are you looking for?)

We will be sending more information on the deliberative dialogue process, our panelist selection process, and other details.

Don’t miss out on this opportunity to offer your perspectives on an important topic – send your information to rules@lcb.wa.gov, type in the subject line “Attention Kathy Hoffman” today!!

FDA Warns Companies Illegally Selling CBD Products

DISTRICT OF COLUMBIA:  The U.S. Food and Drug Administration issued five warning letters to companies for selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). All five warning letters address the illegal marketing of unapproved CBD products claiming to treat medical conditions. The warning letters include CBD products that are especially concerning from a public health perspective due to the route of administration, including nasal, ophthalmic and inhalation. In addition, they address violations relating to the addition of CBD to food, and the impermissible marketing of CBD products as dietary supplements. Two of the letters also address CBD products illegally marketed for pets, including a product for use in the eye.

“The FDA’s first priority is to protect the health and safety of Americans. Many questions remain regarding the science, safety, effectiveness and quality of products containing CBD,” said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. “We remain focused on exploring potential pathways for CBD products to be lawfully marketed while also educating the public about these outstanding questions of CBD’s safety. Meanwhile, we will continue to monitor and take action, as needed, against companies that unlawfully market their products — prioritizing those that pose the greatest risk of harm to the public.”

The warning letters were issued to:

The FDA has previously sent warning letters to other companies illegally selling unapproved CBD products that claimed to prevent, diagnose, mitigate, treat or cure various diseases, in violation of the FD&C Act. In some cases, there were further violations because CBD was added to food, and some of the products were impermissibly marketed as “dietary supplements.”

The products that are the subject of the letters issued today have not gone through the FDA drug approval process and therefore are considered unapproved new drugs. It is not known whether they are effective for the uses claimed in labeling, what an appropriate dose might be, how they could interact with FDA-approved drugs or other products or whether they have dangerous side effects or other safety concerns. In addition, the manufacturing process of these unapproved CBD-containing drug products has not been subject to FDA review as part of the human or animal drug approval processes, so it is not known what the manufacturing conditions of, or contaminant levels in these products may be.

Under the FD&C Act, any product intended to diagnose, cure, mitigate, treat or prevent a disease, and any product (other than a food) that is intended to affect the structure or function of the body of humans or animals, is a drug. New human and animal drugs must be approved by the FDA or conform to a “monograph” for a particular drug category, as established by FDA’s Over-the-Counter (OTC) Drug Review, before they can be legally marketed as drugs. CBD was not an ingredient considered under the OTC Drug Review.

The FDA has not approved any CBD products other than one prescription drug for the treatment of seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in human patients. CBD has not been approved as a food additive and does not meet the statutory definition of a dietary supplement.

The FDA has requested responses from the companies within 15 working days stating how they will address these issues, or providing their reasoning and supporting information as to why they think the products are not in violation of the law. Failure to adequately address the violations promptly may result in legal action, including product seizure and/or injunction.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Pre-Christmas Cannabis Sales Expected To Hit $400 Million, New Years Sales To Top $81 Million

COLORADO:  Business intelligence from Akerna, an enterprise software, leading compliance technology provider, and developer of the cannabis industry’s first seed-to-sale enterprise resource planning software technology, estimates cannabis sales to spike this holiday season.

“To determine how the Christmas and New Year’s holidays would affect cannabis sales nationally, we took a look at last year to see how sales have been influenced by these holidays,” explains James Ahrendt. “For example, the Friday before Christmas was the second largest single sales day of 2019, while the 7-day period leading up to Christmas was 15% higher grossing than the weekly average of 2019.”

Farmer Tom Lauerman in festive garb

Akerna anticipates that in the week leading up to the start of the Christmas holiday (12/18-12/24), weekly average cannabis sales will increase 15%, generating $400 million.

The Friday preceding Christmas (12/18) will most likely be the largest sales day of the month, experiencing a 74% surge in sales. New Year’s Eve is expected to experience a 68% increase in sales, generating $81 million. The average order total is predicted to be $7 higher than the 2020 average, with adult-consumers spending $79 and medical patients spending $121.

Additional Holiday Season Predictions

Sales by product type:

  • Flower – 45%
  • Cartridge/Pens – 31%
  • Concentrates – 13%
  • Infused Edibles – 9%
  • Other – 2%

Sales by gender

  • Male – 64%
  • Female – 36%

Sales by age

  • Under 30 – 28%
  • 30-40 –30%
  • 40-50 – 19%
  • 50-60 –13%
  • Over 60 – 10%

MÜV™ Medical Cannabis Dispensary To Open In Prime Key West Location

FLORIDA:  AltMed Florida, one of the fastest growing medical cannabis companies in Florida, continues its statewide expansion with a three-day opening in Key West starting Saturday December 5, 2020 at 10am (pending final approvals) for its newest MÜV™ Medical Cannabis Dispensary.

Location: 519 Duval Street, the most popular street in Key West.

“Having MÜV on iconic Duval Street is a feather in our cap. Residents and visitors will now have access to our award-winning products and top-notch service,” said John Tipton, AltMed Florida CEO. “Being in such a high traffic destination, this newest location is a great fit for us. We’re excited about becoming part of the Key West community and building lasting relationships with our patients there.”

With millions of visitors each year, Duval Street is lined with retail shops, restaurants and nightlife hotspots like Sloppy Joe’s Bar, which is a designated National Historic Landmark. Running north to south from the Gulf of Mexico to the Atlantic Ocean, Duval Street is the epicenter of Key West’s famous party atmosphere.

The Key West MÜV is the southernmost dispensary in the continental U.S. – just around the corner from the famous Mile-0 marker and near the Southernmost Point Buoy, both bustling tourist landmarks. MÜV is also located on the same block as the popular Margaritaville Key West Restaurant.

During the opening, staggered over three-days (Dec.5-Dec.7) for crowd mitigation, all licensed Florida medical cannabis patients will receive a one-time use only, one per patient, 25 percent off their entire first purchase. Patients can order online for express pickup at muvfl.com where they will see real-time live inventory including specific strains and potencies of products.

Deemed an essential service during the pandemic, AltMed Florida has been able to expand its workforce to over 700 employees with additional teams coming onboard at each of its 17 new dispensaries this year. With higher demand for products from 28 total dispensaries, AltMed has also generated additional construction employment and staffing with the expansion of its 220,000-square-foot cultivation facility in Apollo Beach.

The newest state-of-the-art MÜV dispensary will offer an extensive selection of award-winning products including flower, pre-rolls, a wide range of vaporizer pens, metered dose inhalers, topicals, oral sprays, patent-pending encapsulation formulations in its tinctures, 72-hour transdermal patches and transdermal gels. MÜV also has one of the widest selections of concentrates for patients needing macro-dosing options.

Like AltMed Florida’s 27 other locations (Apollo Beach, Bradenton, Bonita Springs, Cape Coral, Clearwater, Deerfield Beach, Fort Myers, Gainesville, Jacksonville/San Marco, Jacksonville Beach, Lady Lake, Lakeland, Longwood/Orlando, Lutz, North Port, downtown Orlando, Ormond Beach, Pensacola, Port St. Lucie, Sebastian, Sarasota, St. Petersburg, Shalimar, Tallahassee, Tampa, Wellington and West Palm Beach) MÜV Dispensaries are designed to provide a premium experience – think Apple Store, with a modern design and expert staff that undergoes extensive training.

The MÜV brand already has a wide following in other legal medical cannabis markets, including Arizona, where it has won five Best of Arizona medical cannabis awards. MÜV products are sold exclusively in Florida at MÜV dispensaries because, unlike other states, Florida does not allow wholesale of product between license holders – only products that license holders make themselves can be sold in their dispensaries.

For more information about the new ADA-compliant MÜV Medical Cannabis Dispensary at 519 Duval Street in Key West, including hours and available MÜV products, visit muvfl.com.

California Bureau Of Cannabis Control Announces Public University Research Grant Funding Recipients

CALIFORNIA: The Bureau of Cannabis Control (Bureau) announced that it has awarded $29,950,494 in public university research grant funding to universities across California.

“The research conducted through these public university grants will provide critical information for evaluating our legal cannabis system and its impacts,” Bureau of Cannabis Control Chief Lori Ajax said. “This research will be a valuable tool to inform future cannabis policy in California.”

Research proposals had to fall within one of the several specified categories, including public health, criminal justice and public safety, economic, environmental impacts, and the cannabis industry. A detailed description of the list of research subjects for grant funding can be found in Revenue and Taxation Code section 34019.

In total, the Bureau received more than 100 applications for grant funds up to $2 million for any specific proposal. After a thorough review process, the nearly $30 million was awarded to the following public universities:

Public University Awarded Funding Research Proposal
UC San Francisco  

$2,000,000.00

Comprehensive Analysis of Developmental Cannabis Exposure on Brain, Immune, and Sensory Systems
 

UC Santa Barbara

 

$1,999,191.00

Surface Water Emissions from Cannabis Cultivation Sites: Quantity, Quality, Toxicity, and Relationships to Farmers’ Practices
CSU

Dominguez Hills

 

$1,866,311.00

 

Cannabis Industry in South Bay Los Angeles

UC

Berkeley

$1,827,596.00 Local Regulation of Cannabis in California
UC Los Angeles  

$1,429,001.00

Impact of Cannabis Potency on The Properties, Composition, and Toxicity of Inhaled and Second-Hand Smoke
UC San Francisco $1,384,466.00 Effects of Chronic Cannabis Use on Endothelial Function
 

UC Irvine

 

$1,351,556.00

Exploring Cannabis Policies and Practices That Influence Adolescent Use: Evolution of Local Cannabis Law, Products, Sales, and Marketing
 

UC San Diego

 

$1,321,833.00

The Public Health Impact of Cannabis Legalization in California: A Comprehensive Qualitative and Quantitative Analysis by Age, Gender, Race/Ethnicity, and Regions
UC Los Angeles  

$1,082,815.00

Assessing the Feasibility and Consequences of Implementing a Cannabis Potency Tax in California
UC San Francisco  

$1,067,483.00

The LEAF Study: Lung Effects and Function Associated with Cannabis Use
UC Los Angeles  

$1,048,857.00

Study of Employment Conditions and Equity in California’s Cannabis Industry
 

UC San Francisco

 

$1,038,782.00

Public Health Impacts of State Policies Mandating Point-of- Sale Warning Signs Regarding Cannabis Use During Pregnancy
UC Davis $1,034,730.00 Understanding the Impact of Cannabis Use in Early Psychosis
UC San Diego  

$987,738.00

Evaluating the Impacts of Packaging and Labeling on Cannabis Edible Use among Youth
UC San Francisco $952,540.00 California Cannabis Poisonings Under Proposition 64
 

UC Los Angeles

 

$896,794.00

Assessing the Impact of Proposition 64 on Cannabis Use, Maladaptive Cannabis Use, Cannabis Use Disorder Treatment, and Public Health
UC San Diego  

$887,101.00

The Role of Cannabidiol in Anandamide-Related Improvement in Alexithymia and Health Outcomes
UC Los Angeles  

$781,707.00

A Demographic Analysis of the California Licensed Cannabis Industry and Consumer Market
UC Los Angeles  

$758,517.00

The Impact of Cannabis Marketing on California’s Youth: Neuro-Behavioral Studies for Informing Policy
 

 

UC Davis

 

 

$726,816.00

Cannabis Industry: Assessment of the Location, Structure, Function, and Demographics of Licensed Cannabis, Focusing on Geographical Price Differences, and Differential Impacts of Local Prop-64 Related Regulations on the Competitiveness of Licensed Businesses
UC

Berkeley

 

$658,306.00

Transformation of Unregulated Cannabis Cultivation Under Proposition 64
 

 

UC Davis

 

 

$655,564.00

Economic Impacts: Market Prices for Licensed and Unlicensed Cannabis and the Effects of the Current and Alternate Cannabis Tax Structures and Tax Rates on the Private and Public Sectors in California, Including Government Administrative Costs and Revenues
 

 

UC Davis

 

 

$562,240.00

Environmental Impacts of Cannabis Cultivation in California As Affected by the Farm Economics of Licensed and Unlicensed Cannabis Production, Including Effects of Testing Regulations and Compliance with the Criminal Prohibition of Unlicensed Cannabis
 

UC

Berkeley

 

 

$489,762.00

Assessing Environmental Impacts of Cannabis-Related Noise and Light Disturbance to Inform Management of California Wildlife
UC

Berkeley

 

$465,902.00

Examining Tribal Sovereignty Over Cannabis Permitting on Native Ancestral Lands
CSU

Humboldt

$464,997.00 Cannabis Business Entrepreneurs and Jobs
UC Los Angeles  

$414,183.00

Understanding the Impact of Cannabis Marketing on Cannabis Use Disparities Among Sexual and Gender Minority Youth
UC

Berkeley

 

$328,916.00

Cultivation Bans, Local Control, and the Effects and Efficacy of Proposition 64
UC

Berkeley

 

$319,091.00

Cannabis and Wildfire: Current Conditions, Future Threats, and Solutions for Farmers
UC

Berkeley

 

$314,417.00

Cannabis Water-Use Impacts to Streamflow and Temperature in Salmon-Bearing Streams
UC

Berkeley

$270,269.00 The Effect of Local Cannabis Regulation on Property Prices
UC San Diego  

$235,039.00

Evaluating Risks and Benefits of Cannabis Use by Older Adults: A Pilot Study
CSU

Humboldt

 

$183,015.00

The Economic Impact of Cannabis Legalization in Rural Northern California
 

UC Davis

 

$144,949.00

California Cannabis Workers: Perceptions, Beliefs, and Knowledge of Occupational Health and Industry Hazards

New Jersey Attorney General Grewal Issues Additional Guidance To Prosecutors On Handling Low-Level Marijuana Possession-Related Cases

NEW JERSEY:  Attorney General Gurbir S. Grewal has issued additional guidance to prosecutors concerning the prosecution of low-level marijuana cases, supplementing his August 29, 2018 and November 4, 2020 guidance.

Attorney General Grewal directed all New Jersey municipal, county, and state prosecutors to adjourn, until at least January 25, 2021, any juvenile or adult case solely involving the following marijuana possession-related offenses:

  • possession of marijuana or hashish in violation of N.J.S. 2C:35-10(a)(3);
  • possession of marijuana or hashish in violation of N.J.S. 2C:35-10(a)(4);
  • being under the influence of marijuana or hashish in violation of N.J.S. 2C:35-10(c);
  • failure to make lawful disposition of marijuana or hashish in violation of N.J.S. 2C:35-10(d);
  • use or possession with intent to use drug paraphernalia under N.J.S. 2C:36-2 involving only marijuana or hashish;
  • possession of a controlled dangerous substance while operating a motor vehicle in violation of N.J.S. 39:4-49.1 involving only marijuana or hashish; and
  • any disorderly persons offense or petty disorderly persons offense subject to conditional discharge pursuant to N.J.S. 2C:36A-1 involving only marijuana or hashish.

For cases involving the above-enumerated charges as well as other offenses, the Attorney General directed prosecutors to use their discretion to either postpone the case in its entirety or seek dismissal, without prejudice, of the marijuana possession-related charge(s) and proceed with prosecution of the remaining charges. Notably, today’s guidance does not affect the prosecution of cases charging distribution of marijuana or possession of marijuana with intent to distribute.

“Fairness demands that we suspend prosecution of marijuana possession-related cases while we await direction from the Legislature on the parameters for decriminalization of marijuana and legalization of regulated adult-use cannabis,” said Attorney General Grewal. “It simply does not make sense or serve justice to proceed with prosecutions on charges that may be foreclosed soon through legislative action.”

Previously, on November 4th, the Attorney General issued guidance to law enforcement emphasizing that they have broad discretion in handling low-level marijuana offenses, and encouraging them to exercise that discretion in light of anticipated legislative action that may decriminalize marijuana.

Attorney General Grewal reiterated that more comprehensive guidance, including direction on handling previously adjudicated matters, will follow when the Legislature provides details of the framework for marijuana decriminalization and the legalization of adult-use cannabis.

Guidance for Marijuana Possession Cases Pending in Municipal and Superior Courts: click here.

Guidance Regarding Municipal Prosecutors’ Discretion in Prosecuting Marijuana and Other Criminal Offenses, August 29, 2018: click here.

Interim Guidance on the Constitutional Amendment Legalizing Cannabis, November 4, 2020: click here.

Missouri Health & Wellness Announces Grand Opening for Cannabis Dispensary in Washington

MISSOURI: Missouri Health & Wellness (MH&W), a medical cannabis company licensed to operate five dispensaries in the state, announced today that its Washington location will be open for business on November 30 th. The Washington location is one of five dispensaries operated by MH&W and was one of the first approved by the Missouri Department of Health and Senior Services (DHSS) to operate in the state. MH&W also owns and operates dispensaries in Belton, Kirksville, Jefferson City and Sedalia.

“This has been a long time coming and we are excited to finally bring medical cannabis to Washington, Franklin County and the surrounding areas,” said Randy Stambaugh, MH&W’s statewide manager. “I can’t say enough about the support we have received from the City of Washington, the business community and the residents.”

ASA Publishes The Medical Cannabis Patient’s Guide For U.S. Travel

Just time for the holidays, Americans For Safe Access (ASA) has published it’s medical cannabis patient’s guide for U.S. travel.  Available online, the flyer provides a handy review of the laws regarding medical cannabis across the country as a service to help patients legally acquire marijuana along their journey.

The Medical Cannabis Patient’s Guide for U.S. Travel is a convenient resource to help you navigate the crazy quilted patchwork of laws governing medical marijuana use in the United States.

Excerpt:

Following the 2020 general election, there are currently 48 states and four territories with some form of a medical cannabis access, as well as 13 states and the District of Columbia that now permit adult-use, but the rights and privileges they extend to medical cannabis patients vary among them. As a result, patients who travel for personal or employment reasons can find themselves unsure as to how to access medical cannabis in an unfamiliar place.

Given the importance of patients knowing the laws regarding medical cannabis in the states and jurisdictions they visit, ASA created The Medical Cannabis Patient’s Guide for U.S. Travel to help patients safely and legally learn how to acquire cannabis while travelling.